Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research Apr 12, 2022
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in… Feb 16, 2022
Ketamine Expert Dr. Reid Robison On Clinical Trials, Ketamine For Eating Disorders, And Novamind’s Plans For Growth Jan 26, 2022
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial Jan 19, 2022